Call us: 1.405.235.2305
info@i2E.org
  • Events
  • News
  • Resources
  • Media
  • Love’s Cup
i2Ei2Ei2Ei2E
  • About
  • Entrepreneurship
    • Venture Advisory Services
    • Love’s Entrepreneur’s Cup
  • e3
  • Concept Fund
  • iMCI
  • Portfolio
  • ACT Tulsa
  • Contact

OMRF receives $1.74 million to investigate cell death

    Home News OMRF receives $1.74 million to investigate cell death
    NextPrevious

    OMRF receives $1.74 million to investigate cell death

    By sarah | News | 0 comment | 3 January, 2017 | 0

    Copyright © 2017, The Oklahoma Publishing Co.

    An Oklahoma Medical Research Foundation scientist has received a four-year federal grant to investigate the biological process of cell death.

    Courtney Griffin/The Oklahoman

    The grant, awarded by the National Heart, Lung, and Blood Institute, will provide $1.74 million to OMRF scientist Courtney Griffin to study what triggers a form of cell death called necroptosis in the vascular system.

    The body uses programmed cell death to carry out specific biological purposes. “It’s an important and essential part of some phases of human development,” Griffin said in a news release. “For example, as embryos, our hands look like little round paddles until programmed cell death kills off the cells between our fingers.”

    This type of cell death that destroys the cells between our fingers is called apoptosis, and it has been studied for decades. However, a newer form of cell death called necroptosis has been identified recently, and Griffin is interested in identifying the causes and effects of necroptosis in blood vessels.

    While apoptosis is often seen as beneficial and orderly, necroptosis appears to be a much uglier form of cell death. In apoptosis, cells die neatly, and other cells come along to clean up behind them, Griffin said. But necroptosis results in a messy sort of cell death, which can cause inflammation and damage to nearby cells in the surrounding tissue.

    One way to compare apoptosis with necroptosis is to imagine two types of building demolition, said Griffin, who joined OMRF’s scientific staff in 2008 from the University of North Carolina at Chapel Hill.

    “Apoptosis is like an implosion, where the building’s walls fall inward onto themselves in a nice, controlled way,” she said. “But in necroptosis, it’s more like when a gas main blows and the building explodes outward. The damage is far greater and more widespread. Both buildings come down, but the resulting damage is vastly different.”

    Griffin’s lab will study the rapidly growing blood vessels in mouse embryos to investigate not only what triggers necroptosis, but also to learn about the secondary effects of the damage imposed by this form of programmed cell death.

    “Understanding the causes and effects of necroptosis on the embryonic vascular system is only the tip of the iceberg,” she said. “We hope our findings may also provide insight into how necroptosis contributes to adult vascular diseases like atherosclerosis and aneurysms.”

    The grant, 1 R01 HL134778-01, is funded through the NHLBI, a part of the National Institutes of Health.

    Source: Oklahoma Medical Research Foundation

    Read the article at newsok.com

     

     

     

     

     

    Courtney Griffin, OMRF, The Oklahoma Medical Research Foundation

    Related Post

    • Linear Health Sciences Announces U.S. FDA Clearance and Health Canada Approval of its Orchid Safety Release Valve (SRV)

      By sarah | Comments are Closed

      Device Intended to Reduce Risk of IV Catheter Failure and Replacement in Hospitals; Sister Product Orchid SRV-Type D for Drainage to Launch Simultaneously OKLAHOMA CITY, Okla. – May 17, 2022 – Medical device company LinearRead more

    • Student teams from OSU, TU and East Central claim Love’s Cup top awards

      By sarah | Comments are Closed

      May 3, 2022 Contact: Sarah Seagraves, Senior VP for Marketing (405) 813-2403 or email sseagraves@i2E.org Teams led by student innovators from Oklahoma State University, the University of Tulsa and East Central University claimed first placeRead more

    • A final column and a thank you for reading

      By sarah | Comments are Closed

      Thank you for reading this column for nearly a decade By Scott Meacham This is my final column for The Oklahoman. As CEO of i2E, I have had the wonderful opportunity since January 2013 to write thisRead more

    • A significant impact on new ventures? That’s i2E’s e3 program

      By sarah | Comments are Closed

      Accelerators like i2E’s e3 can have a significant impact on new ventures By Scott Meacham When the team from Zen Health Technologies formally introduces their company, they describe a business that uses immersive technologies for personalRead more

    • Autigen Announces Collaboration with Boehringer Ingelheim

      By sarah | 0 comment

      Novel Treatments for Hearing Loss Collaboration and licensing agreement to advance novel therapies for sensorineural hearing loss (SNHL), where there are currently no approved pharmacological therapies. OKLAHOMA CITY–(BUSINESS WIRE)– Autigen, a biotechnology portfolio company of theRead more

    Leave a Comment

    You must be logged in to post a comment.

    NextPrevious
    i2E-300dpi-Trans-Light
    • Events
    • News
    • Resources
    • Media
    • Love’s Cup

    Oklahoma City Office

    840 Research Parkway, Suite 250
    OKC, OK 73104
    PHONE 405/235-2305
    Click HERE for printable map with directions.

    Tulsa Office

    100 S. Cincinnati Ave – 5th Floor, Suite 514
    Tulsa, OK 74103
    PHONE 918/582-5592
    Copyright 2022 i2E, Inc. | All Rights Reserved
    • About
    • Entrepreneurship
      • Venture Advisory Services
      • Love’s Entrepreneur’s Cup
      • ACT Tulsa
    • e3
    • Concept Fund
    • Portfolio
    • iMCI
    • ACT Tulsa
    • Contact
    i2E